VRDNHIGH SIGNALFINANCIAL10-K

VRDN shows severe cash burn acceleration with R&D expenses surging 285% and net losses deepening to $343M while cash reserves declined 31%.

The company is experiencing rapid cash consumption driven by massive R&D spending increases, suggesting either significant clinical trial expansion or pipeline advancement that requires substantial capital investment. With declining cash reserves and mounting losses, investors should closely monitor the company's funding runway and potential need for additional capital raises.

Comparing 2026-02-26 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

VRDN's financial position deteriorated significantly with R&D expenses exploding 285% to $35M and SG&A costs rising 56% to $95M, driving net losses deeper to $343M from $270M. The balance sheet shows stress signals with total debt increasing 335% to $20M, total liabilities surging 151% to $177M, and cash declining 31% to $33M. This combination of accelerating expenses, mounting debt, and shrinking cash reserves suggests the biotech is in a capital-intensive development phase that may require near-term funding to sustain operations.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+426.3%
$95K→$500K

Interest expense surged 426.3% — significant debt increase or rising rates materially impacting earnings.

Accounts Receivable
Balance Sheet
+350%
$24K→$108K

Receivables surged 350% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Total Debt
Balance Sheet
+335%
$4.6M→$20.2M

Debt increased 335% — substantial leverage increase; assess whether deployed for growth or covering losses.

R&D Expense
P&L
+285.4%
$9.0M→$34.8M

R&D investment increased 285.4% — signals commitment to future product development, though near-term margin impact.

Total Liabilities
Balance Sheet
+150.5%
$70.8M→$177.3M

Liabilities grew 150.5% — significant increase in debt or obligations, assess impact on financial flexibility.

Inventory
Balance Sheet
-65.8%
$187K→$64K

Inventory drawn down 65.8% — strong sell-through or deliberate destocking; watch for supply constraints.

SG&A Expense
P&L
+56%
$61.1M→$95.3M

SG&A up 56% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Current Liabilities
Balance Sheet
+47.7%
$47.9M→$70.7M

Current liabilities surged 47.7% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
-31.3%
$47.4M→$32.6M

Cash declined 31.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Net Income
P&L
-26.9%
-$269.9M→-$342.6M

Net income declined 26.9% — review whether driven by operations, interest costs, or non-recurring items.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-03
ADDED
As of February 20, 2026, there were 102,206,571 shares of the registrant s common stock outstanding.
Any of our product candidates may fail in development or experience significant delays.
Regulatory approval processes are lengthy, time-consuming and inherently unpredictable, and we may be unable to obtain approval for our product candidates or approval may be delayed due to factors beyond our control, including as a result of disruptions at the FDA and other agencies caused by shutdowns, funding shortages, and policies pursued by the current U.S.
Some of our product candidates have produced results only in nonclinical settings, or for other indications than those for which we contemplate conducting development and seeking FDA or other regulatory approval, and we cannot give any assurance that we will generate data for any of our product candidates sufficiently supportive to receive regulatory approval in our planned indications, which will be required before they can be commercialized.
Even if we obtain regulatory approvals for any of our product candidates, our products will be subject to ongoing regulatory oversight.
+7 more — sign up free →
REMOVED
As of February 20, 2025, there were 81,484,950 shares of the registrant s common stock outstanding.
Regulatory approval processes are lengthy, time-consuming and inherently unpredictable.
Some of our product candidates have produced results only in nonclinical settings, or for other indications than those for which we contemplate conducting development and seeking U.S.
Food and Drug Administration ( FDA ) or other regulatory approval, and we cannot give any assurance that we will generate data for any of our product candidates sufficiently supportive to receive regulatory approval in our planned indications, which will be required before they can be commercialized.
We target disease areas where marketed therapies often leave room for improvements in efficacy, safety, and/or dosing convenience.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →